Peter Zdziarski: Will Glanzmann Thrombasthenia Patients Be Formally Recognized as Benefiting from SevenFACT?
Peter Zdziarski, Founder and Marketing Director of Glanzmann Thrombasthenia Advocacy Network, shared a post on LinkedIn:
“We’re seeing something important in the Glanzmann Thrombasthenia (GT) community.
More patients are using SevenFACT to manage bleeds, with consistently strong feedback.
Given the rarity of this condition and the limited, often unpredictable treatment options, we are always looking for more.
It’s also important to recognize how GT patients approach treatment.
Many prefer on-demand therapies used at the time of a bleed rather than methods requiring ongoing weekly dosing. Flexibility and real-time control are critical.
As real-world use continues to grow, it raises a simple question for HEMA Biologics:
Will Glanzmann Thrombasthenia patients be more formally recognized as a group that can benefit from SevenFACT?
Recognition drives awareness.
Awareness drives access.
And access is everything for rare disease communities.
There’s clear momentum here.
It’s worth paying attention to!”
More posts featuring Peter Zdziarski on Hemostasis Today.
-
May 8, 2026, 09:25Athma Dias: Limitations of PT and APTT in Predicting Thrombotic Risk
-
May 8, 2026, 09:12Abhishek Kumar: New Horizons in Hemophilia B Treatment and Prevention
-
May 8, 2026, 08:19Augustina Isioma Ikusemoro: Thalassaemia is not Just a Blood Disorder – It is a Public Health Priority
-
May 8, 2026, 06:24Transforming Thrombosis Management With Antithrombotic Stewardship – Anticoagulation Forum
-
May 8, 2026, 06:03Risk-Stratified HRT Use Following VTE – NBCA
-
May 7, 2026, 17:56The Latest Clinical Data Shaping The Evolving Landscape of Hemophilia Treatment – EAHAD
-
May 7, 2026, 17:31Talha Badar: New Classical Hematology Chapter on Bleeding and Thrombosis
-
May 7, 2026, 17:26Maria Τektonidou: Gene Network Analysis Identifies STAT1 in Thrombotic APS
-
May 7, 2026, 17:23Sonu Bhaskar: Inflammatory Biomarkers in Acute Cerebral Venous Sinus Thrombosis